Skip to content

Rivaroxaban EP Impurity H

Rivaroxaban EP Impurity H

Product Description
CAT No.
ALN-R017054
CAS No.
1770812-37-7
Mol. F.
C19H17Cl2N3O5S
Mol. Wt.
470.3
Stock
In Stock
Chemical Name : 4,5-dichloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide (as per EP);(S)-4,5-Dichloro-N-({2-oxo-3-[4-(3-oxomorpholino)phenyl]oxazolidin-5-yl}methyl)thiophene-2-carboxamide (as per USP)
Smiles : O=C(C1=CC(Cl)=C(Cl)S1)NC[C@H]2CN(C3=CC=C(N4C(COCC4)=O)C=C3)C(O2)=O
Inchi : InChI=1S/C24H21Cl2N3O7S2/c25-19-7-5-17(37-19)22(32)27-11-16-12-29(24(34)36-16)15-3-1-14(2-4-15)28(9-10-35-13-21(30)31)23(33)18-6-8-20(26)38-18/h1-8,16H,9-13H2,(H,27,32)(H,30,31)/t16-/m0/s1
Synonym : Rivaroxaban USP Related Compound H

Development and validation of stability indicating UPLC method for the determination of Rivaroxaban in bulk and finished products and identification of degradation products by LCMS

By Ali, Syed Mastan; Ramachandran, D.nFrom Journal of Applicable Chemistry (Lumami, India) (2021), 10(3), 291-301

Validated LC-MS/MS method for the determination of three genotoxic impurities in rivaroxaban drug substance

By Korlakunta, Vijaya Gouri; Dasari, Vijaya Bharathi; Sharma, Hemant Kumar; Nowduri, Annapurna; Bonige, Kishore Babu; Chavakula, Ramadas – From European Journal of Biomedical and Pharmaceutical Sciences (2020), 7(8), 492-500

Development of a stability-indicating HPLC method and a dissolution test for rivaroxaban dosage forms

By Souri, Effat; Mottaghi, Siavash; Zargarpoor, Mohammad; Ahmadkhaniha, Reza; Jalalizadeh, Hassan – From Acta Chromatographica (2016), 28(3), 347-361

Request For Quotation